These results also indicated that the [Au(d2pype)2]Cl/ibrutinib combination rendered the cells more sensitive than ibrutinib alone, and suggested that targeting the TrxR and BTK using [Au(d2pype)2]Cl and ibrutinib at the same time may constitute a new, efficient strategy against lymphoma. This evidence concerns the gene BTK and lymphoma.